{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T13:49:44Z","timestamp":1765374584972,"version":"3.46.0"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Canc Conf J"],"DOI":"10.1007\/s13691-025-00785-8","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T06:41:40Z","timestamp":1751870500000},"page":"407-411","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pathologic complete response to enfortumab vedotin plus pembrolizumab in node-positive urothelial carcinoma: a case report"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4524-2815","authenticated-orcid":false,"given":"Takuto","family":"Hara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiki","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoto","family":"Wakita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaaki","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kotaro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Matsuyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taisuke","family":"Tobe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideto","family":"Ueki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Teishima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Miyake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,7]]},"reference":[{"issue":"1","key":"785_CR1","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1097\/MOU.0000000000001230","volume":"35","author":"J Pfail","year":"2025","unstructured":"Pfail J, Lichtbroun B, Golombos DM, Jang TL, Packiam VT, Ghodoussipour S (2025) The role of radical cystectomy and lymphadenectomy in the management of bladder cancer with clinically positive lymph node involvement. Curr Opin Urol 35(1):115\u2013122. https:\/\/doi.org\/10.1097\/MOU.0000000000001230","journal-title":"Curr Opin Urol"},{"issue":"4","key":"785_CR2","doi-asserted-by":"publisher","first-page":"216","DOI":"10.6004\/jnccn.2024.0024","volume":"22","author":"TW Flaig","year":"2024","unstructured":"Flaig TW, Spiess PE, Abern M et al (2024) NCCN Guidelines\u00ae insights: bladder cancer, version 3.2024. J Natl Compr Canc Netw 22(4):216\u2013225. https:\/\/doi.org\/10.6004\/jnccn.2024.0024","journal-title":"J Natl Compr Canc Netw"},{"issue":"10","key":"785_CR3","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles T, Valderrama BP, Gupta S et al (2024) Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med 390(10):875\u2013888. https:\/\/doi.org\/10.1056\/NEJMoa2312117","journal-title":"N Engl J Med"},{"issue":"15_suppl","key":"785_CR4","doi-asserted-by":"publisher","first-page":"TPS4587","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS4587","volume":"39","author":"CJ Hoimes","year":"2021","unstructured":"Hoimes CJ, Bedke J, Loriot Y et al (2021) KEYNOTE-B15\/EV-304: randomized phase 3 study of perioperative enfortumab vedotin plus pembrolizumab versus chemotherapy in cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC). J Clin Oncol 39(15_suppl):TPS4587. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.TPS4587","journal-title":"J Clin Oncol"},{"issue":"19","key":"785_CR5","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","volume":"391","author":"T Powles","year":"2024","unstructured":"Powles T, Catto JWF, Galsky MD et al (2024) Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer. N Engl J Med 391(19):1773\u20131786. https:\/\/doi.org\/10.1056\/NEJMoa2408154","journal-title":"N Engl J Med"},{"issue":"6","key":"785_CR6","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1007\/s10147-024-02503-5","volume":"29","author":"H Miyake","year":"2024","unstructured":"Miyake H, Fujisawa M (2024) Early experience and future prospects regarding use of newly developed surgical robot system, hinotori, in the field of urologic cancer surgery. Int J Clin Oncol 29(6):640\u2013646. https:\/\/doi.org\/10.1007\/s10147-024-02503-5","journal-title":"Int J Clin Oncol"},{"key":"785_CR7","doi-asserted-by":"publisher","first-page":"816444","DOI":"10.3389\/fonc.2022.816444","volume":"12","author":"J Wu","year":"2022","unstructured":"Wu J, Xie RY, Cao CZ, Shang BQ, Shi HZ (2022) Disease management of clinical complete responders to neoadjuvant chemotherapy of muscle-invasive bladder cancer: a review of the literature. Front Oncol 12:816444. https:\/\/doi.org\/10.3389\/fonc.2022.816444","journal-title":"Front Oncol"},{"key":"785_CR8","doi-asserted-by":"publisher","first-page":"232470962412573","DOI":"10.1177\/23247096241257333","volume":"12","author":"KH Chan","year":"2024","unstructured":"Chan KH, Shu T, Al Shaarani M, Cen P (2024) Complete pathologic response with pembrolizumab and enfortumab vedotin in urothelial carcinoma of the upper urinary tract. J Investig Med High Impact Case Rep 12:23247096241257332. https:\/\/doi.org\/10.1177\/23247096241257333","journal-title":"J Investig Med High Impact Case Rep"}],"container-title":["International Cancer Conference Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13691-025-00785-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13691-025-00785-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13691-025-00785-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T12:54:47Z","timestamp":1765371287000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13691-025-00785-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,7]]},"references-count":8,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["785"],"URL":"https:\/\/doi.org\/10.1007\/s13691-025-00785-8","relation":{},"ISSN":["2192-3183"],"issn-type":[{"type":"electronic","value":"2192-3183"}],"subject":[],"published":{"date-parts":[[2025,7,7]]},"assertion":[{"value":"10 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Hideaki Miyake received honoraria from Astellas, AstraZeneca, Bayer, Eisai, Janssen, Merck, MSD, Nippon-Shinyaku, Novartis, Ono, Pfizer, Sanofi, and Takeda. Hideaki Miyake received research funding from MSD, Pfizer, and Ono.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Written informed consent was obtained from the patient for publication of this case and accompanying images.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Ethical approval was not required for this case report in accordance with institutional policy.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Approval of the research protocol by an institutional review board"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Registry and the registration no. of the study\/trial"}}]}}